# Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma

> **NCT03323710** · PHASE2 · WITHDRAWN · sponsor: **Military Institute od Medicine National Research Institute**

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Propranolol
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT03323710
- **Lead sponsor:** Military Institute od Medicine National Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Poor patient recruitment.
- **Last updated:** 2019-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03323710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03323710, "Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03323710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*